![]() (Richards, 2018)Ĭentyrins are small (∼10 kDa) cysteine-free scaffolds based on the 10th type-III fibronectin domain of human fibronectin. Different kinds of scaffolds have been reported to generate SDCs in recently years.įig.1 A diagrammatical representation of various antibody fragments and binding scaffolds. A recent commercial analysis of this space identified 84 unique alternative scaffold products in development with 82% in the preclinical/discovery stage and 40% aimed at oncology. Currently, the majority of applications are for imaging (due to excellent contrast ratios) and receptor/ligand inhibition. coli, selected by in vitro display, and have higher stability. These scaffolds tend to be smaller than antibody fragments ranging from 6-21 kDa, can be expressed at high yield in E. The non-antibody binding scaffold field is emerging commercially after many years of R&D. We are capable of developing different kinds of engineered scaffolds targeting various targets to meet your conjugation needs. Armed with rich experience in scaffold design and synthesis, Creative Biolabs provides comprehensive scaffold-drug conjugates (SDCs) development services for our clients. Besides utilizing antibody fragments as targeting moieties, the protein engineering community has begun to explore alternative high-binding protein scaffolds as antibody mimics. Studies have emerged suggesting that traditional IgG scaffolds may not be the optimal format for targeted payload delivery. ADC Development for Mesothelin-expressing Tumours.ADC Development for Fallopian Tube Cancer.ADC Development for Merkel-cell Carcinoma.ADC Development for Head and Neck Cancer.ADC Development for Colorectal Cancer (CRC).ADC Development for Gastrointestinal Stromal Tumors (GIST).ADC Development for Gastrointestinal Malignancies.ADC Development for Gastrointestinal Cancer.Biparatopic Receptor-based Bispecific ADCs.Fast-internalizing Receptor-based Bispecific ADCs.Antibody Fragment-drug Conjugates Development.Application of Antibody-Oligonucleotide Conjugates (AOC).Conjugation Strategies of AOC Development.Oligonucleotide Synthesis for AOC Development.Antibody-Oligonucleotide Conjugates (AOC) Development Services.Antibody-directed Enzyme Prodrug Therapy (ADEPT).Antibody Discovery Service for Enzyme Conjugate.Antibody-directed Toxic Enzyme Fusion Proteins.Antibody-enzyme Conjugates for Cancer Therapy.Antibody Discovery for Bacterial Infection.
0 Comments
Leave a Reply. |